313 related articles for article (PubMed ID: 15883336)
1. Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis.
Ponseti JM; Azem J; Fort JM; López-Cano M; Vilallonga R; Buera M; Cervera C; Armengol M
Neurology; 2005 May; 64(9):1641-3. PubMed ID: 15883336
[TBL] [Abstract][Full Text] [Related]
2. Experience with starting tacrolimus postoperatively after transsternal extended thymectomy in patients with myasthenia gravis.
Ponseti JM; Azem J; Fort JM; López-Cano M; Vilallonga R; Gamez J; Armengol M
Curr Med Res Opin; 2006 May; 22(5):885-95. PubMed ID: 16709310
[TBL] [Abstract][Full Text] [Related]
3. Tacrolimus for myasthenia gravis: a clinical study of 212 patients.
Ponseti JM; Gamez J; Azem J; López-Cano M; Vilallonga R; Armengol M
Ann N Y Acad Sci; 2008; 1132():254-63. PubMed ID: 18096852
[TBL] [Abstract][Full Text] [Related]
4. Post-thymectomy combined treatment of prednisone and tacrolimus versus prednisone alone for consolidation of complete stable remission in patients with myasthenia gravis: a non-randomized, non-controlled study.
Ponseti JM; Gamez J; Azem J; Fort JM; López-Cano M; Vilallonga R; Buera M; Armengol M
Curr Med Res Opin; 2007 Jun; 23(6):1269-78. PubMed ID: 17559724
[TBL] [Abstract][Full Text] [Related]
5. Benefits of FK506 (tacrolimus) for residual, cyclosporin- and prednisone-resistant myasthenia gravis: one-year follow-up of an open-label study.
Ponseti JM; Azem J; Fort JM; Codina A; Montoro JB; Armengol M
Clin Neurol Neurosurg; 2005 Apr; 107(3):187-90. PubMed ID: 15823673
[TBL] [Abstract][Full Text] [Related]
6. Tacrolimus in refractory patients with myasthenia gravis: coadministration and tapering of oral prednisolone.
Shimojima Y; Matsuda M; Gono T; Ishii W; Tokuda T; Ikeda S
J Clin Neurosci; 2006 Jan; 13(1):39-44. PubMed ID: 16307880
[TBL] [Abstract][Full Text] [Related]
7. Influence of ectopic thymic tissue on clinical outcome following extended thymectomy in generalized seropositive nonthymomatous myasthenia gravis.
Ponseti JM; Gamez J; Vilallonga R; Ruiz C; Azem J; López-Cano M; Armengol M
Eur J Cardiothorac Surg; 2008 Nov; 34(5):1062-7. PubMed ID: 18760934
[TBL] [Abstract][Full Text] [Related]
8. Long-term effects of infrasternal mediastinoscopic thymectomy in myasthenia gravis.
Murai H; Uchiyama A; Mei FJ; Kojima M; Kira J
J Neurol Sci; 2009 Dec; 287(1-2):185-7. PubMed ID: 19726063
[TBL] [Abstract][Full Text] [Related]
9. Tacrolimus Improves Symptoms of Children With Myasthenia Gravis Refractory to Prednisone.
Liu C; Gui M; Cao Y; Lin J; Li Y; Ji S; Bu B
Pediatr Neurol; 2017 Dec; 77():42-47. PubMed ID: 29074055
[TBL] [Abstract][Full Text] [Related]
10. Effects of FK506 on myasthenia gravis patients with high interleukin-2 productivity in peripheral blood mononuclear cells.
Utsugisawa K; Nagane Y; Yonezawa H; Obara D; Kondoh R; Tohgi H
Muscle Nerve; 2003 Feb; 27(2):245-8. PubMed ID: 12548534
[TBL] [Abstract][Full Text] [Related]
11. Five-year follow-up with low-dose tacrolimus in patients with myasthenia gravis.
Minami N; Fujiki N; Doi S; Shima K; Niino M; Kikuchi S; Sasaki H
J Neurol Sci; 2011 Jan; 300(1-2):59-62. PubMed ID: 21035148
[TBL] [Abstract][Full Text] [Related]
12. Long-term therapeutic efficacy and safety of low-dose tacrolimus (FK506) for myasthenia gravis.
Tada M; Shimohata T; Tada M; Oyake M; Igarashi S; Onodera O; Naruse S; Tanaka K; Tsuji S; Nishizawa M
J Neurol Sci; 2006 Aug; 247(1):17-20. PubMed ID: 16631797
[TBL] [Abstract][Full Text] [Related]
13. Beneficial effect of tacrolimus on myasthenia gravis with thymoma.
Mitsui T; Kunishige M; Ichimiya M; Shichijo K; Endo I; Matsumoto T
Neurologist; 2007 Mar; 13(2):83-6. PubMed ID: 17351528
[TBL] [Abstract][Full Text] [Related]
14. Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis.
Dau PC; Lindstrom JM; Cassel CK; Denys EH; Shev EE; Spitler LE
N Engl J Med; 1977 Nov; 297(21):1134-40. PubMed ID: 917042
[TBL] [Abstract][Full Text] [Related]
15. Clinical predictors of steroid-induced exacerbation in myasthenia gravis.
Bae JS; Go SM; Kim BJ
J Clin Neurosci; 2006 Dec; 13(10):1006-10. PubMed ID: 17074487
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy and cytokine network-modulating effects of tacrolimus in myasthenia gravis.
Furukawa Y; Yoshikawa H; Iwasa K; Yamada M
J Neuroimmunol; 2008 Mar; 195(1-2):108-15. PubMed ID: 18262659
[TBL] [Abstract][Full Text] [Related]
17. Response to therapy in myasthenia gravis with anti-MuSK antibodies.
Evoli A; Bianchi MR; Riso R; Minicuci GM; Batocchi AP; Servidei S; Scuderi F; Bartoccioni E
Ann N Y Acad Sci; 2008; 1132():76-83. PubMed ID: 18567856
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy and immunological impact of tacrolimus in Chinese patients with generalized myasthenia gravis.
Zhao CB; Zhang X; Zhang H; Hu XQ; Lu JH; Lu CZ; Xiao BG
Int Immunopharmacol; 2011 Apr; 11(4):519-24. PubMed ID: 21195813
[TBL] [Abstract][Full Text] [Related]
19. Antibodies to AChR, MuSK and VGKC in a patient with myasthenia gravis and Morvan's syndrome.
Díaz-Manera J; Rojas-García R; Gallardo E; Juárez C; Martínez-Domeño A; Martínez-Ramírez S; Dalmau J; Blesa R; Illa I
Nat Clin Pract Neurol; 2007 Jul; 3(7):405-10. PubMed ID: 17611489
[TBL] [Abstract][Full Text] [Related]
20. Cyclosporine in the treatment of myasthenia gravis.
Lavrnic D; Vujic A; Rakocevic-Stojanovic V; Stevic Z; Basta I; Pavlovic S; Trikic R; Apostolski S
Acta Neurol Scand; 2005 Apr; 111(4):247-52. PubMed ID: 15740576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
